Sudeshna C Bose
- Assistant Professor, Neurology - (Clinical Scholar Track)
- Assistant Professor, Pharmacy Practice-Science
- Associate Clinical Professor, Neurology - (Clinical Series Track)
- Clinical Associate Professor, (Clinical Series Track)
Contact
Biography
Sudeshna C Bose, MD is a practicing Neurologist in Tucson, Az. Dr.Bose graduated from Calcutta University, Nil Ratan Sircar Medical College and has been in practice for 30 years. Dr.Bose also specializes in movement disorder. She currently practices at Banner University Medical Tucson and is affiliated with Tucson Children's clinic for Rehabilitative Services. Dr.Bose accepts and is contracted with most insurance plans.
Degrees
- M.B.B.S.
- Calcutta University, Nil Ratan Sircar Medical College, India
Work Experience
- N.R.S Medical College Hospital, Calcutta Univeristy (1988 - 1989)
- NRS Medical college Hospital, Calcutta University (1987 - 1988)
Licensure & Certification
- Board Certified in Neurology (2003)
- Pharmacy Practice & Science Joint Appointment (2013)
- Arizona Medical License (2000)
- M.B.B.S., Calcutta University, Nil Ratan Sircar Medical College (1990)
Interests
Research
Treatment of parkinson's disease & movement.
Teaching
She teaches Parkinson's - Movement disorder. Medical Students, Neurology Residents, Psychiatry Resident and Pharmacy Residents.
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Bose, S., Frankl, J. A., & Kuo, P. H. (2018). False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine.. Journal of nuclear medicine technology, 46(2), 149-150. doi:10.2967/jnmt.117.201558More infoDopamine transporter SPECT is an accurate adjunct to clinical evaluation for Parkinson disease when the diagnosis is difficult. Dopaminergic medications may significantly affect dopamine transporter availability and, thus, uptake of dopamine transporter tracers. A patient had a false-positive dopamine transporter SPECT result while she was taking dextroamphetamine and amphetamine for attention-deficit hyperactivity disorder. The SPECT findings normalized after amphetamine therapy was withheld. An accurate medication history combined with knowledge of drugs that interfere with dopamine transporter imaging is critical to ensure accuracy.
